Skip to main content

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Recruiting · Phase 1, Phase 2 · NCT06362252

Conditions: Extensive Stage-small Cell Lung Cancer

At a glance

Research payments reported, 2025
$2.4M
U.S. investigators named
26
Sites paid
33
Planned or actual enrollment
123

About the trial

Sponsor
Daiichi Sankyo (with Merck Sharp & Dohme LLC)
Tested
Ifinatamab deruxtecan (drug), Atezolizumab (drug), Carboplatin (drug)
Dates
Started 2024-07-22; completion 2028-02-20
Results posted
Not yet

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

From ClinicalTrials.gov, last updated 2026-10-01. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Daiichi Sankyo Inc. reported $2.4M in research payments for this study in 2025 (1,832 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.